How big is the preeclampsia drugs market today, and what are its future growth expectations?
The preeclampsia drugs market size has grown rapidly in recent years. It will grow from $1.25 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increased maternal health awareness, research and development, neonatal health concerns, early detection.
The preeclampsia drugs market size is expected to see rapid growth in the next few years. It will grow to $2.12 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to personalized medicine, non-invasive diagnostic tools, targeted therapies, health equity initiatives. Major trends in the forecast period include preventive strategies, patient-centered care, continuous monitoring, regulatory focus.
Get Your Free Sample of The Global Preeclampsia Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp
What are the top drivers to the rising demand in the preeclampsia drugs market?
The rise in diabetes cases among pregnant women is expected to propel the growth of the preeclampsia drug market going forward. Diabetes is a metabolic disease that is chronic and characterized by high blood glucose (or blood sugar) levels. Preeclampsia is a harmful pregnancy condition with elevated blood pressure and organ damage. Metformin, a preeclampsia medicine, is widely used in pregnant women with preterm preeclampsia. For instance, in December 2022, according to the National Library of Medicine, a US-based biomedical library and center of biomedical informatics, the total incidence of gestational diabetes mellitus (GDM) was 20,865 cases, an increase of 6.56% in 2022. Therefore, the rise in diabetes cases among pregnant women will drive the preeclampsia drug market.
How is the preeclampsia drugs market segmented?
The preeclampsia drugs market covered in this report is segmented –
1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management, Proteinuria Monitoring, Lifestyle Modifications
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy, Emergency Delivery Management
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report
Who are the top competitors in the preeclampsia drugs market?
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Celgene Corp, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Siemens Healthcare GmbH, Boehringer Ingelheim Group, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Union Chimique Belge SA, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co Ltd., Mallinckrodt Pharmaceuticals Limited, Comanche Biopharma Corp, Genentech Inc., Diabetomics Inc.
What significant trends should we anticipate in the preeclampsia drugs market over the forecast period?
Major companies in the preeclampsia medicine market are focusing on developing cutting-edge drug solutions to boost their market position. For instance, in March 2023, Comanche Biopharma Corp., a US-based biopharmaceutical firm, revealed that the Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for CBP-4888 Comanche’s unique siRNA treatment to treat preeclampsia. CBP-4888 is a siRNA therapy given subcutaneously and reduces the synthesis of soluble fms-like tyrosine kinase-1 (sFLT1) in the placenta. The placenta’s overproduction of the protein sFLT1, which enters the mother’s circulation, is the primary cause of preeclampsia. CBP-4888 can alleviate the symptoms of preeclampsia, such as high blood pressure and organ damage and may allow for the safe extension of pregnancy.
Which regional trends are influencing the preeclampsia drugs market, and which area dominates the industry?
North America was the largest region in the preeclampsia drugs market in 2024. The regions covered in preeclampsia drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Preeclampsia Drugs Market Report 2025 Offer?
The preeclampsia drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Preeclampsia drugs refer to medications that manage and treat the condition of pre-eclampsia, a serious pregnancy complication characterized by high blood pressure and damage to organs such as the liver and kidneys. These drugs are typically prescribed by healthcare professionals to pregnant women diagnosed with preeclampsia to help lower blood pressure and prevent further complications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13025
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
